Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.48)
# 896
Out of 5,241 analysts
210
Total ratings
47.55%
Success rate
20.31%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GHRS GH Research | Maintains: Overweight | $25 → $35 | $21.39 | +63.63% | 2 | May 15, 2026 | |
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $10.37 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $21.40 | +30.84% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $228.77 | -34.43% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $227.72 | -32.81% | 22 | Feb 19, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $77.47 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $8.76 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $30.08 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $30.09 | +92.76% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $37.48 | +14.73% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $75.85 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.76 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $158.42 | -2.16% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.73 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $18.62 | +87.97% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $6.28 | +107.01% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.14 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.02 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $31.18 | +9.04% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $36.77 | +35.98% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $6.92 | -27.75% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.99 | +303.59% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $54.39 | +6.64% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.31 | +83,869.47% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $7.14 | +1,020.45% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.32 | +127.27% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $2.91 | +278.01% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $9.75 | +23.08% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $9.06 | +1,754.30% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $4.64 | +331.03% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $35.70 | +460.30% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $2.63 | +52.09% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.30 | +10,976.92% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.29 | +210.08% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $67.12 | -41.90% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $56.37 | -73.39% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $2.85 | +6,215.79% | 1 | Oct 9, 2017 |
GH Research
May 15, 2026
Maintains: Overweight
Price Target: $25 → $35
Current: $21.39
Upside: +63.63%
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.37
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $21.40
Upside: +30.84%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $228.77
Upside: -34.43%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $227.72
Upside: -32.81%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $77.47
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.76
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $30.08
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $30.09
Upside: +92.76%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $37.48
Upside: +14.73%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $75.85
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.76
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $158.42
Upside: -2.16%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.73
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $18.62
Upside: +87.97%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $6.28
Upside: +107.01%
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.02
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $31.18
Upside: +9.04%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $36.77
Upside: +35.98%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $6.92
Upside: -27.75%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.99
Upside: +303.59%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $54.39
Upside: +6.64%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.31
Upside: +83,869.47%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $7.14
Upside: +1,020.45%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.32
Upside: +127.27%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $2.91
Upside: +278.01%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $9.75
Upside: +23.08%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $9.06
Upside: +1,754.30%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $4.64
Upside: +331.03%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $35.70
Upside: +460.30%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $2.63
Upside: +52.09%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.30
Upside: +10,976.92%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.29
Upside: +210.08%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $67.12
Upside: -41.90%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $56.37
Upside: -73.39%
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $2.85
Upside: +6,215.79%